These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31358008)

  • 21. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
    Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
    Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
    Respir Med; 2019; 158():59-66. PubMed ID: 31605923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized study of the effects of Aerochamber Plus
    Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
    Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.
    Dorinsky P; DePetrillo P; Siddiqui S; Maes A; Reisner C
    Pulm Pharmacol Ther; 2018 Aug; 51():18-25. PubMed ID: 29763659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
    Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects.
    Huang Y; Assam PN; Feng C; Su R; Dorinsky P; Gillen M
    Pulm Pharmacol Ther; 2020 Oct; 64():101976. PubMed ID: 33152467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
    Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
    Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
    [No Abstract]   [Full Text] [Related]  

  • 30. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history.
    Muro S; Kawayama T; Sugiura H; Seki M; Duncan EA; Bowen K; Marshall J; Megally A; Patel M
    Respir Res; 2024 Aug; 25(1):297. PubMed ID: 39103901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
    Lipworth BJ; Collier DJ; Gon Y; Zhong N; Nishi K; Chen R; Arora S; Maes A; Siddiqui S; Reisner C; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2969-2984. PubMed ID: 30310273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults.
    Maes A; DePetrillo P; Siddiqui S; Reisner C; Dorinsky P
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):223-233. PubMed ID: 29901860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Gon Y; Nishi K; Sato K; Maes A; Siddiqui S; Hayashi N; Hirata H; Martin UJ; Reisner C
    Respir Investig; 2021 Jan; 59(1):135-144. PubMed ID: 32917556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
    Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
    Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
    Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
    De Backer W; De Backer J; Verlinden I; Leemans G; Van Holsbeke C; Mignot B; Jenkins M; Griffis D; Ivanov S; Fitzpatrick J; St Rose E; Martin UJ; Reisner C
    Ther Adv Respir Dis; 2020; 14():1753466620916990. PubMed ID: 32380894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial.
    Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Trivedi R; Jenkins M; Darken P; Aurivillius M; Dorinsky P
    Respir Med; 2021; 185():106509. PubMed ID: 34171789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Usmani O; Roche N; Wahab E; Israel S; Jenkins M; Trivedi R; Dorinsky P; Aurivillius M
    Respir Res; 2021 Oct; 22(1):261. PubMed ID: 34620167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.